Use of M-M-R II outside of the routinely recommended age range – a systematic literature review

References

• Centers for Disease Control and Prevention (CDC). Complications of measles. [Internet]; 2020 [accessed 2020 October 30]. https://www.cdc.gov/measles/symptoms/complications.html .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Epidemiology and prevention of vaccine-preventable diseases. Appendix E: data and statistics. Impact of Vaccines in the 20th and 21st Centuries; 2020 [accessed 2020 Nov 17]. https://www.cdc.gov/vaccines/pubs/pinkbook/downloads/appendices/e/impact.pdf .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Measles cases and outbreaks. [Internet]; 2020 [accessed 2020 October 30]. https://www.cdc.gov/measles/cases-outbreaks.html .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Rubella in the U.S. [Internet]; 2020 [accessed 2020 Nov 17]. https://www.cdc.gov/rubella/about/in-the-us.html .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Mumps cases and outbreaks. [Internet]; 2020 [accessed 2020 Nov 17]. https://www.cdc.gov/mumps/outbreaks.html .
   Google Scholar
• Marin M, Broder KR, Temte JL, Snider DE, Seward JF. Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2010 May 7;59(RR–3):1–12.
   PubMedGoogle Scholar
• European Centre for Disease Prevention and Control (ECDC). ECDC vaccine scheduler: recommended vaccinations: measles, Mumps, Rubella [Internet]. [accessed 2020 Dec 14]. https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=8&SelectedCountryIdByDisease=−1;https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=9&SelectedCountryIdByDisease=−1;https://vaccine–schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=10&SelectedCountryIdByDisease=−1 .
   Google Scholar
• Centers for Disease Control and Prevention (CDC). Measles, mumps, and rubella (MMR) vaccination: what everyone should know [Internet]. [accessed 2020 December 14]. https://www.cdc.gov/vaccines/vpd/mmr/public/index.html .
   Google Scholar
• World Health Organization (WHO). Measles vaccines: WHO position paper - April 2017. Wkly Epidemiol Rec [Internet]. 2017 Apr 28;92(17):205–27. http://apps.who.int/iris/bitstream/10665/255149/1/WER9217.pdf?ua=1 .
   PubMedGoogle Scholar
• Zucker JR, Rosen JB, Iwamoto M, Arciuolo RJ, Langdon-Embry M, Vora NM, Rakeman JL, Isaac BM, Jean A, Asfaw M, et al. Consequences of undervaccination — measles outbreak, New York City, 2018–2019. N Engl J Med. 2020;382(11):1009–17. doi:10.1056/NEJMoa1912514.
   PubMed Web of Science ®Google Scholar
• Kuehn BM. Drop in vaccination causes surge in global measles cases, deaths. Jama. 2021 Jan 19;325(3):213.
   Web of Science ®Google Scholar
• Higgins JPTTJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. Cochrane handbook for systematic reviews of interventions version 6.1 (updated September 2020). [Internet]; 2020 www.training.cochrane.org/handbook .
   Google Scholar
• Redd SC, King GE, Heath JL, Forghani B, Bellini WJ, Markowitz LE. Comparison of vaccination with measles-mumps-rubella vaccine at 9, 12, and 15 months of age. J Infect Dis. 2004 May 01;189(SUPPL. 1):S116–S22. doi:10.1086/378691.
   PubMed Web of Science ®Google Scholar
• Dos Santos BA, Stralioto SM, Siqueira MM, Ranieri TS, Bercini M, Schermann MT, Wagner MB, Silveira TR. Prevalence of antibodies against measles, mumps, and rubella before and after vaccination of school-age children with three different triple combined viral vaccines, Rio Grande do Sul, Brazil, 1996. Revista Panamericana De Salud Publica/Pan Am J Public Health. 2006Nov;20(5), 299–306.
   PubMed Web of Science ®Google Scholar
• Diaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martinez D, Trumbo SP, Fernandez de Castro J. Antibody persistence in children aged 6-7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017 May 25;35(23):3116–22. doi:10.1016/j.vaccine.2017.04.027.
   PubMed Web of Science ®Google Scholar
• Diaz-Ortega JL, Bennett JV, Castaneda D, Martinez D, Fernandez de Castro J. Antibody persistence in young adults 1 year after MMR immunization by aerosol or by subcutaneous route. Vaccine. 2010 Oct 18;28(44):7228–32. doi:10.1016/j.vaccine.2010.08.055.
   PubMed Web of Science ®Google Scholar
• Sarno MJ, Blase E, Galindo N, Ramirez R, Schirmer CL, Trujillo-Juarez DF. Clinical immunogenicity of measles, mumps and rubella vaccine delivered by the Injex jet injector: comparison with standard syringe injection. Pediatr Infect Dis J. 2000;19(9):839–42. doi:10.1097/00006454-200009000-00006.
   PubMed Web of Science ®Google Scholar
• Gothefors L, Bergstrom E, Backman M. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age. Scand J Infect Dis. 2001;33(7):545–49. doi:10.1080/00365540110026593.
   PubMedGoogle Scholar
• Cassidy WM, Jones G, Williams K, Deforest A, Forghani B, Virella G, Venters C. Safety and immunogenicity of concomitant versus nonconcomitant administration of hepatitis B, tetanus-diphtheria, and measles-mumps-rubella vaccines in healthy eleven- to twelve-year-olds. J Adolesc Health. 2005 Mar;36(3):187–92. doi:10.1016/j.jadohealth.2004.02.021.
   PubMed Web of Science ®Google Scholar
• Abu-Elyazeed R, Jennings W, Severance R, Noss M, Caplanusi A, Povey M, Henry O. Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: a phase III, randomized study. Hum Vaccin Immunother. 2018 Nov 02;14(11):2624–31. doi:10.1080/21645515.2018.1489186.
   PubMed Web of Science ®Google Scholar
• Dos Santos BA, Ranieri TS, Bercini M, Schermann MT, Famer S, Mohrdieck R, Maraskin T, Wagner MB. An evaluation of the adverse reaction potential of three measles-mumps-rubella combination vaccines. Revista Panamericana De Salud Publica/Pan Am J Public Health. 2002 Oct 01;12(4):240–46.
   PubMedGoogle Scholar
• Marin M, Marlow M, Moore KL, Patel M. Recommendation of the advisory committee on immunization practices for use of a third dose of mumps virus-containing vaccine in persons at increased risk for mumps during an outbreak. Mmwr. Morbidity Mortality Weekly Rep. 2018 Jan 12;67(1):33–38. doi:10.15585/mmwr.mm6701a7.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, Juni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JAC, et al. The cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011 Oct;18(343):d5928. doi:10.1136/bmj.d5928.
   Web of Science ®Google Scholar
• Grey Literature International Steering Committee (GLISC). Guidelines for the production of scientific and technical reports: how to write and distribute grey literature, Version 1.0. 2006; [accessed 2019 Sep 12]. http://eprints.rclis.org/7469/1/nancy.pdf .
   Google Scholar
• Farace DJ, Schöpfel J. Introduction grey literature. 0.1 definitions. Grey literature in library and information studies. Berlin; New York: De Gruyter Saur; 2010. 1. https://library.oapen.org/handle/20.500.12657/45661?show=full
   Google Scholar
• Schöpfel J. Towards a Prague definition of grey literature. at: twelfth international conference on grey literature: transparency in grey literature grey tech approaches to high tech issues; 2010 Dec 6-7; Prague (Czech Republic). 2019. https://archivesic.ccsd.cnrs.fr/sic_00581570 .
   Google Scholar